Analysis for TMO

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $10.60B in 2024 Q3 to about $11.99B in 2026 Q2, a roughly +13% gain. Net income grew from about $1.63B to about $1.74B, up around 7%, with a peak of $1.97B in 2025 Q4. The trend is constructive, supported by steady operating income and a resilient mix. Operating cash flow remained robust, roughly $1.4B–$3.5B per quarter, peaking at $3.46B in 2025 Q4, while investing cash flow was negative as growth is funded. The arc suggests durable top-line growth and solid cash generation.

💰 Margins & Cash Flow

Margins run in the mid-teens, with net income margin around 14–16% of Revenues and operating income consistently positive. Cash flow from operations is strong; investing activities are negative, reflecting growth investments. Free cash flow has been additive in several quarters, supporting balance-sheet strength.

🛡️ Balance Sheet & Liquidity

The balance sheet shows a large asset base of about $100B, with Equity around $49–53B and Long-term Debt in the mid‑$30B range, implying solid leverage. Current assets exceed current liabilities, supporting resilience.

⚠️ Key Drivers & Risks

• Drivers: Healthcare/Life Sciences spending; lab instrumentation demand.
• Risks: Budget cyclicality in government/pharma; currency and input-cost sensitivity; modest valuation sensitivity.